The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients

Go down

The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients

Post  Jon Moulton on Fri Feb 16, 2018 4:29 pm

Alshareef A, Irwin MS, Gupta N, Zhang H-F, Haque M, Findlay SD, Seong BKA, Lai J, Rayis M, Al-Dandan S, Lai R. The absence of a novel intron 19-retaining ALK transcript (ALK-I19) and MYCN amplification correlates with an excellent clinical outcome in neuroblastoma patients. Oncotarget. 2018; 9:10698-713. doi:10.18632/oncotarget.24216
avatar
Jon Moulton

Posts : 5604
Join date : 2010-03-12
Age : 55
Location : Philomath, Oregon, USA

View user profile http://www.gene-tools.com

Back to top Go down

Back to top

- Similar topics

 
Permissions in this forum:
You cannot reply to topics in this forum